

## **Supplementary Materials**

**Overview:** The parent cohort (PREVAIL III: Ebola Natural History Study) collected a large amount of data with the potential to analyze. Supplemental Tables 1 and 2 demonstrate how our use of hypotheses restricted our analyses of clinical finding to a select few. Even after restricting our analyses, we acknowledge the potential to organize clinical findings at the organ system level and individual symptom level. The baseline clinical findings found in Supplemental Table 3 are organized as organ systems, which grouped some symptoms, and offers another way to interpret the findings, which may be particularly attractive for clinicians. Subsequent to baseline, measurements of stigma did not occur at every study visit, and while established in the literature, stigma and clinical findings declined over time. We provide these additional but important details in Supplemental Tables 4, 5, and 6.

Body System	Clinical Finding	Findings associated with EVD survivors	Additional findings associated with psychosomatic illness
Constitutional	Fever		
	Chills		
	Night sweats		
	Weight loss		
	Weight gain		
	Fatigue		
Ear, nose and throat	Decreased hearing		
	Tinnitus		
	Pain		
	Discharge from ear		
	Discharge from nose		
	Hoarseness		
	Nose bleeds		
Breast	Lumps		
	Nipple Discharge		
	Pain		
Cardiovascular	Palpitations		
	Chest pain		
	Shortness of breath		
	Paroxysmal nocturnal dyspnea		
	Orthopnea		
	Claudication		
	Edema		
Respiratory	Wheezing		
	Dyspnea		
	Cough/sputum		
	Hemoptysis		
	Positive TB skins test		
	Congestion		
Gastrointestinal	Dysphagia		
	Anorexia		
	Nausea		Nausea
	Vomiting		Vomiting
	Hematemesis		
	Diarrhea		Diarrhea
	Melena		
	Rectal bleeding		
	Change in bowel habits		
Jaundice			
	Abdominal pain		Abdominal pain
Genitourinary	Dysuria		
	Hematuria		
	Frequency	Frequency	
	Polyuria		
	Urgency		
	Hesitancy		
	Incontinence		
	Nocturia		

Male reproductive	Penile discharge Testicular pain or mass Infertility Impotence/deceased libido Orchitis	Impotence/deceased libido
Female reproductive	Menarche Menopause Postmenopausal symptoms Painful periods Odor Decreased libido Amenorrhea Abnormal vaginal bleeding	
Musculoskeletal	Joint pain Edema Heat Redness Stiffness Deformity Muscle pain or tenderness	Joint pain Muscle pain or tenderness
Neurological	Headache Syncope Dizziness Vertigo Seizures Loss of vision Diplopia Paresthesia Paralysis Weakness in any limbs Tremor Ataxia Memory loss	Headache Memory loss
Lymphatic Eye	Enlargement of lymph nodes Blurry vision Pain in eye Sensitivity to light Eye redness Discharge from eye Itchy eyes	

Supplemental Table 1: Self-reported symptoms collected by PREVAIL III and its use in study hypotheses.

Body System	Clinical Finding	Findings associated with EVD survivors
Head and face	Deformity Swelling Asymmetry	
Ears, nose and throat	Nose: Deformity/mass Nose: Mucosa Nose: Ulcer Ear: Tympanic membrane Ear: External canal Ear: Hearing Mouth/throat: Mucosa Mouth/throat: Mass Mouth/throat: Ulcer Mouth/throat: Missing teeth Mouth/throat: Dental caries	
Chest	Wheezes Decreased breath sounds Heart murmur Pericardial rub Rales/crackles	} Chest
Abdomen	Splenomegaly Hepatomegaly Mass Tenderness Distension	} Abdomen
Extremities	Deformity Edema Cyanosis Decreased pulse Bruit	
Musculoskeletal	Atrophy Weakness Tenderness Swelling/effusion Synovial tenderness Deformity Decreased range of motion	} Musculoskeletal
Neurologic	Cognition Speech Tremor Reflexes Cranial nerve(s) Focal weakness Gait/balance Sensory	} Neurologic
Skin	Rash Mass Lesion Jaundice Pigmentation	
Breast	Mass Skin retraction Nipple discharge	

Ophthalmic	Uveitis	Uveitis
	Cataract	
	Pseudophakia	
	Macular edema	
	Retinal detachment	
	Dry eye	
	Presbyopia	
	Ocular allergy	

Supplemental Table 2: Physical examination findings collected by PREVAIL III and its use in study hypotheses

Clinical Symptom Group	Odds ratio (95% CI)	p-value
Constitutional symptoms	1.15 (1.03, 1.28)	0.015
Musculoskeletal symptoms	1.19 (1.08, 1.32)	0.001
Genitourinary symptoms	1.2 (1.08, 1.32)	0.001
Neurological symptoms	1.07 (0.97, 1.18)	0.171
Gastrointestinal symptoms	1.17 (1.06, 1.3)	0.002
Eye symptoms	0.9 (0.81, 1)	0.061
Chest exam findings	1.06 (0.86, 1.31)	0.574
Neurologic exam findings	1.01 (0.83, 1.24)	0.902
Abdominal exam findings	1.2 (1.07, 1.35)	0.003
Musculoskeletal exam findings	1.00 (0.84, 1.19)	0.997

Supplemental Table 3: Associations between EVD-related stigma and groups of clinical findings at baseline adjusting for age, sex, education, referral to medical care and HIV status

	Baseline	Visit 2 (6 months)	Visit 3 (12 months)	Visit 4 (18 months)
	N=859	N=755	N=759	N=740
Fatigue	19.9%	9.5%	5.7%	1.2%
Nausea	7.7%	2.4%	2.1%	0.3%
Abdominal pain	24%	11.9%	12.6%	9.2%
Decreased libido	18.5%	10.9%	6.5%	2.7%
Muscle pain	24.7%	15.5%	14.2%	8.4%
Joint pain	51.1%	38.1%	30.7%	21.5%
Headache	48.9%	39.1%	34.5%	19.1%
Urinary frequency	15.9%	2.8%	2.4%	1.1%
Memory loss	31.2%	11.8%	5.3%	0.9%
Eye redness	30.2%	22.5%	15.5%	7.7%
Uveitis <sup>1</sup>	28.4%	-	21.1%	-
Chest exam findings	5.1%	2.6%	1.6%	0.9%
Neurologic exam findings	5.6%	3.6%	1.6%	0.9%
Abdominal exam findings	19.1%	13%	13.3%	12.8%
Musculoskeletal exam findings	8.3%	4.4%	3.3%	1.8%

1. The percentages of uveitis cases at visit 1 and visit 3 are measured out of 793 and 475 participants respectively.

Supplemental Table 4: Clinical findings at each visit

	Baseline N=859	Visit 4 (18 months) N=740
Forced to change residence because of social alienation from family?	213 (24.8%)	26 (3.5%)
Lost a job or another source of income because of being infected?	302 (35.2%)	10 (1.4%)
Lost a spouse because of fear of being infected?	72 (8.4%)	5 (0.7%)
Deprived from attending gathering (e.g., school, church, social)?	97 (11.3%)	3 (0.4%)
Isolated yourself from family and/or friends?	174 (20.3%)	15 (2%)
Withdrew from education/training or did not take up an opportunity?	104 (12.1%)	0 (0%)
Afraid that someone would not want to be sexually intimate?	188 (21.9%)	3 (0.4%)

Supplemental Table 5: EVD-related stigma at study baseline and follow-up

	Visit 1 (Baseline)	Visit 2 (Month 6)	Visit 3 (Month 12)	Visit 4 (Month 18)
<b>Data collection</b>				
Clinical findings	X	X	X	X
Stigma index	X			X
<b>Available data for analyses</b>				
Concurrent associations: Clinical findings and stigma	X			X
Lagged associations: Clinical findings cause stigma			X	X
Lagged associations: Stigma causes clinical findings	X	X		

Supplemental Table 6: PREVAIL III Measurement Timeline and Available Data for Analyses